ZUSDURI Shows Exceptional 36-Month Durability with Median Response Not Reached in Pivotal ENVISION Trial
URGN has more than doubled off its 52-week low of $3.42.
Summary
UroGen Pharma announced highly positive 36-month duration of response (DOR) data for its approved drug ZUSDURI from the pivotal Phase 3 ENVISION trial. Notably, the median DOR has still not been reached, and 64.5% of patients who achieved a complete response maintained it at 36 months. This significant clinical update follows the company's robust Q1 2026 financial results, which already highlighted strong revenue growth driven by ZUSDURI sales. The exceptional durability data, particularly the unreached median DOR, significantly reinforces ZUSDURI's value proposition as a non-surgical treatment for recurrent LG-IR-NMIBC. This data supports its potential to shift the treatment paradigm, reduce the burden of repeated surgical interventions, and drive sustained market adoption and revenue for UroGen Pharma. Investors will be watching for continued market penetration and sales growth of ZUSDURI.
At the time of this announcement, URGN was trading at $30.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $3.42 to $32.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.